Scott Biller

Scott Biller is an Executive Venture Partner at GV, where they seek innovative investment opportunities in biopharma. They retired as Chief Scientific Officer of Agios Pharmaceuticals at the end of 2019 after over nine years in the role, during which they contributed to the discovery of two approved medicines for acute myeloid leukemia. Scott has also held various leadership positions at notable companies such as Novartis and Bristol-Myers Squibb, where they played a pivotal role in the development of multiple investigational and approved drugs. They earned a B.S. in chemistry from MIT, a Ph.D. in organic chemistry from Caltech, and completed a postdoctoral fellowship at Columbia University. Currently, Scott serves on several biotech boards and advisory panels.